[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100450608":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":20,"locations":25,"responsibleParty":58,"collaborators":20,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":20,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":20,"maxAge":20,"enrollmentInfo":68,"targetDuration":20,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":82,"overallStatus":28,"whyStopped":20,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"The Foundation for Orthopaedics and Regenerative Medicine","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment Group (AlloRx)","EXPERIMENTAL","intravenous and sub-tenon delivery (total dose of 100 million cells)",[13],"Biological: AlloRx",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","AlloRx","cultured allogeneic adult umbilical cord derived mesenchymal stem cells",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Chadwick Prodromos, MD","PRINCIPAL_INVESTIGATOR",[26,44],{"facility":27,"status":28,"city":29,"state":20,"zip":20,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Medical Surgical Associates Center","RECRUITING","St John's","Antigua and Barbuda","AG",{"type":33,"coordinates":34},"Point",[35,36],-61.84329,17.12096,{"lat":36,"lon":35},[39],{"name":40,"role":41,"phone":42,"phoneExt":20,"email":43},"Chadwick Prodromos, M.D.","CONTACT","8476996810","care@thepsci.com",{"facility":45,"status":28,"city":46,"state":20,"zip":20,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":53,"contacts":54},"Center for Investigation in Tissue Engineering and Cellular Therapy","Buenos Aires","Argentina","AR",{"type":33,"coordinates":50},[51,52],-58.37723,-34.61315,{"lat":52,"lon":51},[55],{"name":40,"role":41,"phone":42,"phoneExt":56,"email":57},"202","Care@thepsci.com",{"type":59,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100450608","phase-1-safety-of-cultured-allogeneic-adult-umbilical-cord-derived-mesenchymal-stem-cells-for-naion-100450608",false,"NCT05147701","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for NAION","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Non-arteritic Ischemic Optic Neuropathy","Inclusion Criteria:\n\n* Diagnosis of NAION (non-arteritic ischemic optic neuropathy)\n* Understanding and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Clinically significant Abnormalities on pre-treatment laboratory evaluation\n* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.\n* Continued drug abuse\n* Pre-menopausal women not using contraception\n* Previous organ transplant\n* Hypersensitivity to sulfur","ALL",{"count":69,"type":70},20,"ESTIMATED","INTERVENTIONAL",[73],"PHASE1","This trial will study the safety and efficacy of intravenous and sub-tenon delivery of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of non-arteritic ischemic optic neuropathy",[76,77,78,79,80,81],"Eye Diseases","Retinitis Pigmentosa","Diabetic Retinopathy","Macular Degeneration","Traumatic Optic Neuropathy","Optic Atrophy",[76,77,83,78,79,80,81],"stem cell treatment","2025-04-15",{"date":86,"type":87},"2025-04-17","ACTUAL",{"date":89,"type":87},"2022-02-01",{"date":91,"type":70},"2026-01",{"name":5,"class":6},2]